pharma news

News

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

News

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.

News

TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.

News

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.

News

Recent biotech financings are headed by LifeMine's $263m for a transplant drug, with Expedition, Ratio, Vedanta, and Mironid also in on the action.

News

Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."